SRI International

Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. AstraZeneca Offloads Phase III-Ready Su

Bristol-Myers Squibb Co. reported Phase II results in psoriasis for BMS-986165, a selective inhibitor of tyrosine kinase 2 (TYK2), that show what the company's TYK2 program development lead John Thro

In the market for minimally invasive surgery (MIS) products, one of the hottest and fastest growing segments is robotically assisted surgical devices (RASD). In the last 15 years, Intuitive Surgical

Nobel Pharma Japan has entered into a license agreement with SRI International , an independent non-profit research and development organization based in California, regarding the domestic clinica